- Home
- EQR vs BIIB Comparison
EQR vs BIIB Comparison
Compare EQR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQR
- BIIB
- Stock Information
- Founded
- EQR 1993
- BIIB 1978
- Country
- EQR United States
- BIIB United States
- Employees
- EQR N/A
- BIIB N/A
- Industry
- EQR Real Estate Investment Trusts
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- EQR Real Estate
- BIIB Health Care
- Exchange
- EQR Nasdaq
- BIIB Nasdaq
- Market Cap
- EQR 27.9B
- BIIB 25.1B
- IPO Year
- EQR 1993
- BIIB 1991
- Fundamental
- Price
- EQR $74.96
- BIIB $156.95
- Analyst Decision
- EQR Buy
- BIIB Buy
- Analyst Count
- EQR 20
- BIIB 25
- Target Price
- EQR $74.39
- BIIB $260.48
- AVG Volume (30 Days)
- EQR 1.6M
- BIIB 1.7M
- Earning Date
- EQR 10-30-2024
- BIIB 10-30-2024
- Dividend Yield
- EQR 3.66%
- BIIB N/A
- EPS Growth
- EQR 35.67
- BIIB 10.05
- EPS
- EQR 2.44
- BIIB 11.06
- Revenue
- EQR $2,940,829,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- EQR N/A
- BIIB N/A
- Revenue Next Year
- EQR $3.82
- BIIB N/A
- P/E Ratio
- EQR $30.32
- BIIB $14.10
- Revenue Growth
- EQR 3.33
- BIIB N/A
- 52 Week Low
- EQR $56.05
- BIIB $153.63
- 52 Week High
- EQR $78.83
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- EQR 51.71
- BIIB 18.57
- Support Level
- EQR $73.38
- BIIB $153.62
- Resistance Level
- EQR $74.68
- BIIB $175.86
- Average True Range (ATR)
- EQR 1.29
- BIIB 4.55
- MACD
- EQR 0.22
- BIIB -1.32
- Stochastic Oscillator
- EQR 83.84
- BIIB 6.29
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 299 apartment communities with around 80,000 units and is developing three additional properties with 977 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.